Validity of S-100 B in patients after brain radiation

S. Gripp, M. Peiper, C. Matuschek, C. Giro, G. Steinbach, D. Hermsen, M. van Griensven, Wilfried Budach, R. Engers, P. A. Gerber, H. Hefter, B. Spiess, K. Orth, E. Bölke

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Background: S-100B is a calcium binding acute phase protein and a potential biomarker for brain injury. In prior studies elevated plasma S-100B levels were detected in stroke and severe head trauma. The aim of this study was to evaluate whether S-100 B is elevated during cerebral radiotherapy and whether that is associated with adverse outcomes. Material and Methods: In this prospective pilot study, 45 patients (25 males, 20 females, median age 58 [17-81]) underwent cerebral radiation therapy because of a primary or metastaic cerebral malignancy. 39 patients were included in the evaluation. 6 patients died during the study period. S-100 plasma concentrations were measured with an electrochemiluminescence immunoassay on admission and weekly during radiation therapy for the duration of 6 weeks. In 10 healthy young volunteers (5 males, 5 females, median age 32 [28-36]) S-100 B plasma levels were measured weekly for 6 weeks as a negative control. Furthermore, in an active control 10 patients (4 males, 6 females, median age 68 [64-76]) with stroke (7 = major stroke, 3 = lacunar infarct) S- 100 B plasma levels were measured for 7 consecutive days after the event. Results: During radiotherapy S-100 B plasma concentrations increased from median baseline values of 0.030 μg/l to 0.044 μg/l. For the time of radiation therapy most patients showed a mild increase, but absolute plasma values were still within the normal range. In the control group of healthy volunteers S-100 B remained unchanged. In stroke patients S-100 B increased to maximum values of 1.7 μg/l three days after the event. In the 3 patients with lacunar infarcts no increase of S-100 B levels could be detected. Conclusion: Brain irradiation leads to a mild increase of S-100 B plasma levels. However, the absolute rise was far weaker compared to that seen in major brain injuries. Implication Statement: Location: University of Düsseldorf, Structure: S-100 is a sensitive and early marker for brain damage.

Original languageEnglish
Pages (from-to)299-303
Number of pages5
JournalEuropean Journal of Medical Research
Issue number6
StatePublished - 24 Jun 2008
Externally publishedYes


  • Acute phase response
  • Cerebral radiation theraphy
  • Neurological complications
  • S100 B


Dive into the research topics of 'Validity of S-100 B in patients after brain radiation'. Together they form a unique fingerprint.

Cite this